KCNN4 as a genomic determinant of cytosolic delivery by the attenuated cationic lytic peptide L17E.

ABSTRACT: The development of a cytosolic delivery strategy for biopharmaceuticals is one of the central issues in drug development. Knowledge of the mechanisms underlying these processes may also pave the way for the discovery of novel delivery systems. L17E is an attenuated cationic amphiphilic lytic (ACAL) peptide developed by our research group that shows promise for cytosolic antibody delivery. In this study, given the high efficacy of L17E in cytosolic delivery, we investigated the mechanism of action of L17E in detail. L17E was found to achieve cytosolic delivery predominantly by transient disruption of the plasma membrane without the need for endocytosis. Importantly, the cell-line selectivity studies of L17E revealed a strong correlation between the efficiency of L17E-mediated delivery and t

SUBMITTER: Kuriyama M 

PROVIDER: S-EPMC11852704 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature